

# Hendrikus Jan Dubbink

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3429881/publications.pdf>

Version: 2024-02-01

54  
papers

2,968  
citations

257450

24  
h-index

197818

49  
g-index

54  
all docs

54  
docs citations

54  
times ranked

4361  
citing authors

#	ARTICLE	IF	CITATIONS
1	Combined molecular subtyping, grading, and segmentation of glioma using multi-task deep learning. <i>Neuro-Oncology</i> , 2023, 25, 279-289.	1.2	34
2	Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial. <i>Clinical Cancer Research</i> , 2022, 28, 2527-2535.	7.0	27
3	Fast detection of FOXF1 variants in patients with alveolar capillary dysplasia with misalignment of pulmonary veins using targeted sequencing. <i>Pediatric Research</i> , 2021, 89, 518-525.	2.3	4
4	The clonal relation of primary upper urinary tract urothelial carcinoma and paired urothelial carcinoma of the bladder. <i>International Journal of Cancer</i> , 2021, 148, 981-987.	5.1	12
5	Comparison of variant allele frequency and number of mutant molecules as units of measurement for circulating tumor DNA. <i>Molecular Oncology</i> , 2021, 15, 57-66.	4.6	28
6	The leading role of pathology in assessing the somatic molecular alterations of cancer: Position Paper of the European Society of Pathology letter to the Editor. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 379-380.	2.8	1
7	Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations. <i>Acta Neuropathologica</i> , 2021, 141, 945-957.	7.7	32
8	Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma. <i>Neuro-Oncology</i> , 2021, 23, 1547-1559.	1.2	34
9	Molecular Genetics of Conjunctival Melanoma and Prognostic Value of TERT Promoter Mutation Analysis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5784.	4.1	15
10	Overcoming Acquired Resistance Mutation MET D1228N to Crizotinib With Cabozantinib in NSCLC With MET Exon 14 Skipping Mutation. <i>JCO Precision Oncology</i> , 2021, 5, 849-853.	3.0	7
11	Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC) Tj ETQq1 <i>Oncology, The</i> , 2021, 22, 813-823.	10.7	132
12	Clinical Validation of Whole Genome Sequencing for Cancer Diagnostics. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 816-833.	2.8	47
13	Response Letter. <i>Journal of Thoracic Oncology</i> , 2021, 16, e56.	1.1	0
14	The Erasmus Glioma Database (EGD): Structural MRI scans, WHO 2016 subtypes, and segmentations of 774 patients with glioma. <i>Data in Brief</i> , 2021, 37, 107191.	1.0	13
15	Gynecological Surveillance and Surgery Outcomes in Dutch Lynch Syndrome Carriers. <i>Cancers</i> , 2021, 13, 459.	3.7	2
16	In-depth molecular analysis of combined and co-primary pulmonary large cell neuroendocrine carcinoma and adenocarcinoma. <i>International Journal of Cancer</i> , 2021, , .	5.1	6
17	Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria. <i>Neuro-Oncology</i> , 2020, 22, 515-523.	1.2	140
18	Plasma Predictive Features in Treating EGFR-Mutated Non-Small Cell Lung Cancer. <i>Cancers</i> , 2020, 12, 3179.	3.7	11

#	ARTICLE	IF	CITATIONS
19	Topographical Mapping of 436 Newly Diagnosed IDH Wildtype Glioblastoma With vs. Without MGMT Promoter Methylation. <i>Frontiers in Oncology</i> , 2020, 10, 596.	2.8	13
20	TP53 Mutations in Serum Circulating Cell-Free Tumor DNA As Longitudinal Biomarker for High-Grade Serous Ovarian Cancer. <i>Biomolecules</i> , 2020, 10, 415.	4.0	23
21	Impact of panel design and cut-off on tumour mutational burden assessment in metastatic solid tumour samples. <i>British Journal of Cancer</i> , 2020, 122, 953-956.	6.4	21
22	MET immunohistochemistry: a reliable screening tool for MET exon 14 skipping mutations in non-small cell lung cancer?. <i>Annals of Translational Medicine</i> , 2020, 8, 1538.	1.7	0
23	Differences in spatial distribution between WHO 2016 low-grade glioma molecular subgroups. <i>Neuro-Oncology Advances</i> , 2019, 1, vdz001.	0.7	9
24	Predicting the 1p/19q Codeletion Status of Presumed Low-Grade Glioma with an Externally Validated Machine Learning Algorithm. <i>Clinical Cancer Research</i> , 2019, 25, 7455-7462.	7.0	70
25	Response to: An immunohistochemical approach to detect oncogenic CTNNB1 mutations in primary neoplastic tissues. <i>Laboratory Investigation</i> , 2019, 99, 445-446.	3.7	0
26	Recommendations for the clinical interpretation and reporting of copy number gains using gene panel NGS analysis in routine diagnostics. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 673-680.	2.8	24
27	Prognostic relevance of mutations and copy number alterations assessed with targeted next generation sequencing in IDH mutant grade II glioma. <i>Journal of Neuro-Oncology</i> , 2018, 139, 349-357.	2.9	24
28	A novel tissue-based $\beta$ -catenin gene and immunohistochemical analysis to exclude familial adenomatous polyposis among children with hepatoblastoma tumors. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26991.	1.5	17
29	SNPitty. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 166-176.	2.8	13
30	The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation study. <i>Neuro-Oncology</i> , 2018, 20, 1393-1399.	1.2	139
31	The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis. <i>Neuro-Oncology</i> , 2018, 20, 103-112.	1.2	220
32	Clinical evaluation of a dedicated next generation sequencing panel for routine glioma diagnostics. <i>Acta Neuropathologica Communications</i> , 2018, 6, 126.	5.2	38
33	Multicenter Evaluation of the Idylla NRAS-BRAF Mutation Test in Metastatic Colorectal Cancer. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 664-676.	2.8	19
34	Correlation of Gene Mutation Status with Copy Number Profile in Uveal Melanoma. <i>Ophthalmology</i> , 2017, 124, 573-575.	5.2	26
35	Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas: assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratification. <i>Acta Neuropathologica</i> , 2017, 134, 957-959.	7.7	87
36	Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. <i>Lancet, The</i> , 2017, 390, 1645-1653.	13.7	307

#	ARTICLE	IF	CITATIONS
37	Metastatic Disease in Polyploid Uveal Melanoma Patients Is Associated With <i>BAP1</i> Mutations. , 2016, 57, 2232.		16
38	Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifen. <i>Oncotarget</i> , 2016, 7, 43412-43418.	1.8	30
39	Cost-effectiveness of routine screening for Lynch syndrome in endometrial cancer patients up to 70 years of age. <i>Gynecologic Oncology</i> , 2016, 143, 453-459.	1.4	43
40	Diagnostic Detection of Allelic Losses and Imbalances by Next-Generation Sequencing. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 775-786.	2.8	64
41	Cost-effectiveness of routine screening for Lynch syndrome in colorectal cancer patients up to 70 years of age. <i>Genetics in Medicine</i> , 2016, 18, 966-973.	2.4	42
42	Oligonucleotide-directed mutagenesis screen to identify pathogenic Lynch syndrome-associated <i>MSH2</i> DNA mismatch repair gene variants. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 4128-4133.	7.1	28
43	Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. <i>Neuro-Oncology</i> , 2016, 18, 388-400.	1.2	143
44	<i>TP53</i> mutated glioblastoma stem-like cell cultures are sensitive to dual mTORC1/2 inhibition while resistance in <i>TP53</i> wild type cultures can be overcome by combined inhibition of mTORC1/2 and Bcl-2. <i>Oncotarget</i> , 2016, 7, 58435-58444.	1.8	8
45	Guidelines on Genetic Evaluation and Management of Lynch Syndrome. <i>American Journal of Gastroenterology</i> , 2015, 110, 192-193.	0.4	3
46	Mitochondrial D310 mutation as clonal marker for solid tumors. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2015, 467, 595-602.	2.8	12
47	Guidelines on genetic evaluation and management of Lynch syndrome. <i>Gastrointestinal Endoscopy</i> , 2015, 81, 243-244.	1.0	4
48	Next generation diagnostic molecular pathology: Critical appraisal of quality assurance in Europe. <i>Molecular Oncology</i> , 2014, 8, 830-839.	4.6	44
49	Prevalence and Implications of <i>TERT</i> Promoter Mutation in Uveal and Conjunctival Melanoma and in Benign and Premalignant Conjunctival Melanocytic Lesions. , 2014, 55, 6024.		74
50	Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. <i>Lancet Oncology</i> , The, 2014, 15, 943-953.	10.7	639
51	<i>TERT</i> promoter mutations and <i>BRAF</i> mutations are rare in sporadic, and <i>TERT</i> promoter mutations are absent in <i>NF1</i> -related malignant peripheral nerve sheath tumors. <i>Journal of Neuro-Oncology</i> , 2014, 120, 267-272.	2.9	17
52	A review on the molecular diagnostics of Lynch syndrome: a central role for the pathology laboratory. <i>Journal of Cellular and Molecular Medicine</i> , 2010, 14, 181-197.	3.6	62
53	Androgen Receptor Ligand-Binding Domain Interaction and Nuclear Receptor Specificity of FXXLF and LXXLL Motifs as Determined by L/F Swapping. <i>Molecular Endocrinology</i> , 2006, 20, 1742-1755.	3.7	42
54	Distinct Recognition Modes of FXXLF and LXXLL Motifs by the Androgen Receptor. <i>Molecular Endocrinology</i> , 2004, 18, 2132-2150.	3.7	102